Monsanto intends to sell Posilac business

by Keith Nunes
Share This:

ST. LOUIS — The Monsanto Co. is in the process of divesting its Posilac bovine somatotropin business unit. Posilac is a treatment dairymen may use to increase milk production in their herd. It also has been the center of controversy for some time.

"While Posilac is a strong product for the business, we believe repositioning the business with a strategic owner will allow Monsanto to focus on the growth of its core seeds and traits business while ensure that loyal dairy farmers continue to receive the value of Posilac in their operations," said Carl Casale, executive vice-president of strategy and operations for Monsanto.

Several major milk processors have banned their producers from using the treatment. In addition, companies like Ben & Jerry’s Homemade Holdings, Inc., and Kraft Foods Inc., market products as being free of the supplement.

Comment on this Article
We welcome your thoughtful comments. Please comply with our Community rules.

The views expressed in the comments section of Food Business News do not reflect those of Food Business News or its parent company, Sosland Publishing Co., Kansas City, Mo. Concern regarding a specific comment may be registered with the Editor by clicking the Report Abuse link.